Literature DB >> 11144928

Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.

S Desai1, S D Lim, R E Jimenez, T Chun, T E Keane, J K McKenney, A Zavala-Pompa, C Cohen, R H Young, M B Amin.   

Abstract

The aim of this study was to assess the relationship of immunoreactivity of cytokeratin 20 (CK20) and CD44 across the spectrum of urothelial neoplasia using the WHO/ISUP consensus classification. A total of 120 papillary urothelial pTa and pT1 tumors (8 papillomas, 8 neoplasms of low malignant potential, and 42 low-grade and 62 high-grade carcinomas) were immunostained by using CK20 and CD44 antibodies. The relationships of tumor grade, pathologic stage, recurrences, and progression in stage with CK20 and CD44 immunoreactivity were assessed. WHO/ISUP grade correlated with tumor stage (P < 0.005), recurrence (P = 0.02), and progression in stage (P = 0.031). Normal urothelium showed CK20 immunoreactivity restricted to a few umbrella cells. Expression of CD44 in normal urothelium was restricted to the basal cell layer. Loss of CD44 immunoreactivity and increasing CK20 positivity were significantly associated with increasing tumor grade and stage (P < 0.005). An inverse relationship was observed in the staining patterns of CK20 and CD44 within individual cases, as well as in the aggregate data, with 79.2% of tumors with CD44 loss showing CK20 positivity (P < 0.001). In conclusion, CK20 and CD44 immunoreactivity are significantly related to the WHO/ISUP grade and to each other, and our data suggest their potential combined utility in predicting biologic behavior in patients with papillary urothelial pTa and pT1 neoplasms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144928     DOI: 10.1038/modpathol.3880241

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

Review 1.  Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies.

Authors:  R Montironi; A Lopez-Beltran; R Mazzucchelli; D G Bostwick
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

2.  [Molecular markers in the diagnostics and therapy of urothelial cancer].

Authors:  C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

3.  Karyometry detects subvisual differences in chromatin organisation state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential.

Authors:  M Scarpelli; R Montironi; L M Tarquini; P W Hamilton; A López Beltran; J Ranger-Moore; P H Bartels
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

4.  In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Authors:  Johannes Breyer; Ralph M Wirtz; Wolfgang Otto; Philipp Erben; Maximilian C Kriegmair; Robert Stoehr; Markus Eckstein; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann
Journal:  Virchows Arch       Date:  2017-01-10       Impact factor: 4.064

Review 5.  [Urinary bladder tumours. The new 2004 WHO classification].

Authors:  M Seitz; D Zaak; R Knüchel-Clarke; C Stief
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 6.  When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.

Authors:  David J DeGraff; Justin M Cates; Joshua R Mauney; Peter E Clark; Robert J Matusik; Rosalyn M Adam
Journal:  Urol Oncol       Date:  2011-09-15       Impact factor: 3.498

7.  Tumour Behaviour of Low-Grade Papillary Urothelial Carcinoma: A Single-Centre Retrospective Study.

Authors:  Satya Dutta; Biswajit Dey; Vandana Raphael; Yookarin Khonglah; Jaya Mishra; Evarisalin Marbaniang; Pranjal Kalita; Stephen Sailo
Journal:  Cureus       Date:  2021-06-29

8.  A study of cytokeratin 20 immunostaining in the urothelium of neuropathic bladder of patients with spinal cord injury.

Authors:  Subramanian Vaidyanathan; Ian W McDicken; Anna J Ikin; Paul Mansour; Bakul M Soni; Gurpreet Singh; Pradipkumar Sett
Journal:  BMC Urol       Date:  2002-07-29       Impact factor: 2.264

9.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.